| Bid | 0.8 |
| Market Cap | 75.48M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.44 |
| PE Ratio (ttm) | -1.8 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.83 |
| Volume | 748,193 |
| Avg. Volume (20D) | 791,083 |
| Open | 0.80 |
| Previous Close | 0.81 |
| Day's Range | 0.78 - 0.83 |
| 52-Week Range | 0.73 - 1.80 |
| Beta | undefined |
About ASRT
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, ...
Analyst Forecast
According to 4 analyst ratings, the average rating for ASRT stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 279.46% from the latest price.
Next Earnings Release
Analysts project revenue of $28.67M, reflecting a -13.08% YoY shrinking and earnings per share of 0.01, making a -90.91% decrease YoY.
2 months ago · businesswire.com
Buxton Helmsley Releases Evidence of Product-Related Fraud at AssertioNEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity pos...
